Telemedicine

Two options for Telemedicine visits

QR codes for Eyecare live

We have added Telemedicine to our practice to give our patients continued access to care during the coronavirus pandemic. You will be able to communicate with Dr Titone, send pictures, text or even video conference. Eyecare live can be used with an app or app-less.  You have to use a smart phone For the  App but Eyecarelive can be used from any browser  app-less! Download the app from the links above or scan the QR code with your smart device. Come See what we can do!

The New Panoptix IOL

With an Expanded visual range
See near, Far and in between
Click Here
Previous slide
Next slide

 Food and Drug Administration (FDA) has approved and its initial commercial launch of AcrySof®IQ PanOptix®Trifocal Intraocular Lens (IOL), the first and only trifocal lens for U.S. patients undergoing cataract surgery. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery.

PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to high-quality distance vision in a range of lighting conditions. The new lens uses ENLIGHTEN®Optical Technology, a proprietary design that optimizes intermediate vision without compromising near and distance vision. Available in spherical and toric designs, PanOptix is built on Alcon’s proven AcrySof IQ IOL platform that has been implanted in more than 120 million eyes globally.

The AcrySof® IQ PanOptix® Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the AcrySof® IQ PanOptix® Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would.

AcrySof® IQ PanOptix® Trifocal IOL  will be avaliable soon at East Carolina Center for Sight, Ask Dr Titone if this is the right lens for your cataract surgery. 

FDA approves update to IOL master 700 to include posterior corneal measurements

Dr Titone at East Carolina Center for Sight has been selected to be one of the first in the USA to receive the new Total Keratometry upgrade for the IOLMaster 700. This will allow us to select the best possible Lens power for our cataract surgery patients.

The IOLMaster®700 from ZEISS with SWEPT Source OCT technology now allows us to directly measure the posterior corneal surface. It combines unique telecentric keratometry measurement of the anterior corneal surface with measurement of the posterior corneal surface in order to calculate Total Keratometry (TK®).

  • There are two exclusive new formulas: Barrett TK Universal II and Barrett TK Toric
The current Barrett Toric Calculator uses a unique eye model to predict the posterior corneal surface. Using Total Keratometry with the Barrett Toric Calculator would thus lead to overcompensation of posterior corneal astigmatism.
Because of this, Graham Barrett has developed two new IOL power calculation formulas: the Barrett TK Universal II for non-toric IOLs, and the Barrett TK Toric for toric IOLs. Both new formulas use posterior corneal surface measurements instead of the eye model used by the Barrett Toric Calculator
  • We Can use existing IOL calculation formulas – no need for a second device, third-party software or an online calculator
This decreases errors in manual data entry and streamlines workflow.
 

East Carolina Center for Sight where Great vision is Our Mission.

 

News from the Kiawah Eye Meeting

Wow! what a meeting. Great Venue, Great Format, Fantastic panel of Ophthalmic surgeons.  Highly recommended to all Ophthalmologist and Eyecare providers.   This meeting presents new groundbreaking techniques, new takes on current techniques as well as those still under study. The interactive case format for complex surgical problems was outstanding. All the speakers were highly accessible and very receptive to any questions.

On to the News.

CXL (cornea collegen crosslinking) studies for ectiasia and Keratoconus

Bill Trattler, M.D and Eric Donnenfeld related their findings of their studies, overall there is great success in halting corneal thinning, there is even some regression. The indications seem to point to early intervention rather than treating advanced cases.  The american studies lean toward epithelium on techniques rather than epithelium off techniques used in Europe.  What is all this in english..and why is it important?  This procedure consists of exposing the front of the eye (the Cornea) to an ultavioloet light source for approximately 30 minutes. The cornea is treated with Riboflavin (one of the B vitamins). The collagen in the cornea becomes crosslinked (forms bridges between individual collagen strands) making the cornea stiffer resisting forward bowing.  The treatment can be done in the doctors office.  The FDA has not approved this treatment in the US yet.  There are several centers involved in studies.

Who is this treatment for:

  • Patients with Keratoconus ( a genetic disease of the cornea causing it to thin and bow forward causing progressive nearsightedness).
  • Patients who have had LASIK of PRK and have ectasia (a condition that causing thinning and progressive nearsightedness)

 

Laser Cataract Surgery

Richard Mckool, Eric Donnenfeld, Dick Lindstrom, Bill Trattler and Ugday Devgan all gave us their take on The New LenSX and LensAR Laser cataract units that are now FDA approved. Optimedica is not far behind and will introduce a unit soon.   They all think these units will allow great improvements in cataract surgery while decreasing patient risk.  The surgeon still has to enter the eye to remove the lens fragments and to insert a new prosthetic lens (IOL).  The units are very expensive to purchase and have a per use fee, This will increase the cost of surgery to the patient.  Most of us doing premium lens surgery will use these lasers in the near future, charging the patient one fee for Refractive Cataract surgery with a premium lens and Laser incisions with Laser assisted cataract removal (LACR).  See the Videos below. Exciting times to be an Ophthalmologist!

[vsw id=”xoL5qvOro_4″ source=”youtube” width=”425″ height=”344″ autoplay=”0″]

[vsw id=”FgdiXwOtxc4″ source=”youtube” width=”425″ height=”344″ autoplay=”0″]

[vsw id=”JHeT27ivKDo” source=”youtube” width=”425″ height=”344″ autoplay=”0″]

 

Intraocular Lenses

Just a brief  note Alcon quietly introduced a preloaded version of  Its IQ Acrysof lens in a C cartridge along with the other lenses I mentioned in the previous post. These are useful in places where staff is unavailable or unable to load the  lens, decreases chance of contamination or lens damage.  Previously only a B cartridge pre loaded was available, this was unsuitable for small incision surgery.

[vsw id=”x-Tv08nzrkg” source=”youtube” width=”425″ height=”344″ autoplay=”0″]

Lasik guidelines for thin corneas

I spoke with Dr Trattler about LASIK in thin corneas he related there are several studies that now are indicating  LASIK in corneas with less than 500 micron thickness is safe as long as the topography is normal. There is even some indication that PRK may be ok in select Keratoconus patients. The FDA approval of  Collagen crosslinking  will influence the minimum thickness surgeons are comfortable with as it can halt ectasia (progressive thinning) if it occurs. Dr Trattler commented on this in his own Blog recently.
William B. Trattler, MD, focuses his blog on optimizing the results of cataract and refractive surgery.
 
William B. Trattler, MD
LASIK in thin corneas with normal topographies
Posted by William B. Trattler, MD   September 23, 2010 03:37 PM

Having returned from the European Society of Cataract and Refractive Surgeons’ annual meeting in Paris, I feel fortunate to have had the opportunity to see firsthand how many European surgeons approach patients in both cataract and refractive surgery, as they have technologies ranging from topography-guided PRK, toric multifocal implants, toric phakic IOLs and many other interesting devices.

Besides interesting technologies, I also had the chance to learn how Europeans approach various controversial topics in refractive surgery.

Of particular interest to me was the discussion on LASIK in thin corneas. Although some doctors may suggest that any cornea that is not within two standard deviations of the average corneal thickness is “abnormal,” the scientific data strongly support the fact that there is no direct relationship between corneal thickness and corneal strength when corneal topography is normal. And, in fact, we have learned from cross-linking that the same cornea after cross-linking is thinner but significantly stronger.

Obviously, the real question is how do eyes with thin corneas and normal topographies fair with LASIK?

At the ISRS symposium at ESCRS, Dr. Steven Schallhorn shared the latest data from Optical Express, which has numerous LASIK centers distributed throughout Europe.

Dr. Schallhorn shared the results of a series of more than 80,000 eyes that have undergone LASIK, including more than 2,000 eyes with corneas thinner than 500 µm and normal topographies. Dr. Schallhorn noted that the early results reveal that no eyes with thin corneas had developed ectasia, while three cases of ectasia developed in eyes of patients with corneal thickness above 500 µm. When taken in the context of the six peer-reviewed articles in the medical literature that looked at the results of LASIK in thin corneas with normal topography, it is my strong belief that corneal thickness as an isolated parameter has no bearing on the risk of ectasia after LASIK.

Obviously, it is natural for surgeons to work very hard to ensure that topographies of patients with thin corneas do not have any signs suggestive of early keratoconus. As well, it should be noted that some of the European doctors I spoke with still prefer PRK for corneas thinner than 500 µm — but noted that this was not based on any concrete evidence.